Melinta Therapeutics, Inc.

Quick facts

Marketed products

• Kimyrsa · Other

Phase 3 pipeline

• Single-Dose IV Oritavancin Diphosphate · Infectious Diseases
  Oritavancin diphosphate is a lipoglycopeptide antibiotic that inhibits cell wall synthesis in Gram-positive bacteria.

Phase 2 pipeline

• CEM-101 · Oncology
  CEM-101 is a potent and selective inhibitor of the histone deacetylase 6 (HDAC6) enzyme.

Phase 1 pipeline

• Current Formulation of Oritavancin

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Melinta Therapeutics, Inc. portfolio CI brief
• Melinta Therapeutics, Inc. pipeline updates RSS